THE immediate and often dramatic improvement in patients with prostatic cancer, after endocrine treatment, tends to obscure the fact that a relatively small proportion of cases live for more than 5 years (see Franks, 1958, for review). The object of the present investigation was to see whether there were any specific features, using routine clinical and pathological methods, by which patients likely to live for more than 5 years could be recognised at the time of diagnosis.
METHODS
From haematoxylin and eosin stained paraffin sections of the initial biopsy material the tumours were graded, using a similar method to that used in an earlier investigation (Fergusson and Franks, 1952) , and the presence or absence of basophil (" mucoid ") secretion in the tumour and of a surrounding stromal reaction, were recorded. The following clinical points were noted: first symptoms (urinary or due to metastatic disease), whether the prostate was clinically carcinomatous on rectal examination, the presence or absence of metastases on radiological examination when first seen, the formal-stable serum acid phosphatase when first seen, and the cause of death-whether due to prostatic cancer or intercurrent disease. Changes in the clinical state of the prostate, the serum acid phosphatase and the later development of metastases were also studied. The clinical changes in a larger unselected series of cases has been reported in detail by Fergusson (1958) .
RESULTS
The results are shown in detail in Tables I-VI and only the main points will be discussed below. The number of cases in each group and the percentage of Age (Table I ).-The age incidence in both long and short survivors follows the same general pattern in that most of the cases are between 60 and 80 years of age. Only one of the six patients between 50 and 60 years lived for more than 5 years. Apart from this the differences in age distribution in the two groups are probably not significant.
Histological grade (Tables I and II ).-In both groups the number of patients with tumours of a low grade of malignancy is small, but there were more in the group of long survivors. Although rather more of the short survivors had high-grade tumours (58 per cent) nearly 40 per cent of the long survivors also had similar tumours. Thus the survival period is not directly related to the histological malignancy of the tumour. There appears to be no direct association between histological grade and age (Table II) . Stromal reaction to the tumour (Table J) .-Since it might be thought that a stromal reaction in the tumour may represent a response by the host to the tumour, the extent of any fibrous reaction was noted. There are no significant differences between the groups. It has been suggested that a lymphoid reaction around the tumour is associated with a long survival period in cancer of the breast (Moore and Foote, 1949) and stomach (Black, Opler and Speer, 1954) . However, in these prostatic tumours a lymphoid reaction was seen only in association with areas of chronic inflammation, not obviously related to the tumour.
Basophil secretion in the tumours (Table I ).-Many well differentiated prostatic tumours may secrete a basophil mucoid material (Franks, 1954) . Since it has been reported by some workers, e.g. Delbet and Mendaro (1927) and others, that mucoid secretion in breast tumours was associated with a relatively good prognosis, this factor was also assessed. This type of secretion was present more frequently in the long survivors (40 per cent of cases as compared with 26 per cent), but this may only reflect the greater number of relatively well differentiated tumours (average and low grades combined) in this group. (62 per cent as compared with 42 per cent).
First symptoms (Table I ).-In both groups the presenting symptoms were local (urinary) in the great majority but symptoms due to metastasis were commoner in the short survivors-24 per cent as compared with 6 per cent.
Changes on rectal examination (Table 1) (Table IV) . particularly the older men. The younger the patient, the greater the proportion dying as a result of cancer.
Serum acid phosphatase (Table J ).-The serum phosphatase was higher (over 5*0 units) in a larger proportion of short survivors, and remained so after treatment. Benign nodular hyperplasia and prostatic cancer.-Patients with prostatic carcinomas found after prostatectomy, in men with clinically benign prostatic enlargement, tend to have a long survival period (Nesbit and Baum, 1951; Edwards, 1955; Franks, 1956b) . In the series of cases reported here there were 5 such patients among the 32 long survivors (16 per cent) but only 1 (who died from a myocardial infarct) (2 per cent) among the 53 short survivors. One of the long survivors was found to have developed a carcinoma 6 months after a retropubic prostatectomy for benign enlargement. Two of the short survivors had a perurethral resection and one a retropubic prostatectomy for benign enlargement, 4 years, 2 years and 1J years, respectively, before the carcinoma was diagnosed. The number of patients studied are too few to allow a statistical analysis of results but in general, it can be said that there is no single feature which is constantly associated with long survival. The commonest finding in the long survivors was the absence of metastases at the time of diagnosis (78 per cent) but as almost half (49 per cent) the short survivors also had no metastases this is of little value in assessing prognosis in the individual case. A change in the prostate after treatment from clinically malignant to clinically benign generally implies a good prognosis but even here death due to the effects of metastatic deposits is not excluded. A high serum acid phosphatase level (more than 5 formal-stable King-Armstrong units) remaining high after treatment, is generally associated with a short survival period. The histological grade of the tumour does not seem to influence the survival of the patient, or the incidence of metastases. Metastases are much less common in the elderly, i.e. men over 80 years old.
These findings emphasize the need for a reliable method of assessing the biological malignancy of prostatic cancer.
